Bactericidal activity of besifloxacin against staphylococci, Streptococcus pneumoniae and Haemophilus influenzae. - Wikidata - wikimedia - TriplyDB

Bactericidal activity of besifloxacin against staphylococci, Streptococcus pneumoniae and Haemophilus influenzae.

Bactericidal activity of besifloxacin against staphylococci, Streptococcus pneumoniae and Haemophilus influenzae.

http://www.wikidata.org/entity/Q40953254

about

Safety of besifloxacin ophthalmic suspension 0.6% in cataract and LASIK surgery patients Safety of besifloxacin ophthalmic suspension 0.6% in refractive surgery: a retrospective chart review of post-LASIK patients The safety of besifloxacin ophthalmic suspension 0.6 % used three times daily for 7 days in the treatment of bacterial conjunctivitis Besifloxacin: Efficacy and Safety in Treatment and Prevention of Ocular Bacterial Infections Studies on the antimicrobial properties of N-acylated ciprofloxacins.Antibacterial efficacy of prophylactic besifloxacin 0.6% and moxifloxacin 0.5% in patients undergoing cataract surgery.Safety of besifloxacin ophthalmic suspension 0.6% as a prophylactic antibiotic following routine cataract surgery: results of a prospective, parallel-group, investigator-masked study.Contribution of the R8 substituent to the in vitro antibacterial potency of besifloxacin and comparator ophthalmic fluoroquinolones.Besifloxacin ophthalmic suspension, 0.6%: a novel topical fluoroquinolone for bacterial conjunctivitis.The role of besifloxacin in the treatment of bacterial conjunctivitis.Integrated analysis of three bacterial conjunctivitis trials of besifloxacin ophthalmic suspension, 0.6%: etiology of bacterial conjunctivitis and antibacterial susceptibility profile.The role of topical moxifloxacin, a new antibacterial in Europe, in the treatment of bacterial conjunctivitis.Microbiological etiology and susceptibility of bacterial conjunctivitis isolates from clinical trials with ophthalmic, twice-daily besifloxacin.

P2860

Q24562648-209A58F6-2CAF-4517-A633-FE41DC844B8F Q24631003-17771637-0E0B-49DC-8268-C07E3D2C5756 Q24631812-A404B403-7F78-464E-849E-C638849ABE1A Q26752242-C211E45E-9BBD-4C88-9080-AD9C51F82072 Q31096940-FA1A3D84-0C99-43AE-AF74-0B750B0BF617 Q35617621-0605A920-E455-4384-98A2-9A0DD488301B Q36026870-7C66B03F-9ABB-445D-8356-539DD4A90DDA Q36825816-529F1F9A-356B-4C06-BF93-4192AED1DFA5 Q38021408-122DCB85-839F-46E6-BBBC-580EDA9126D5 Q38190827-D8A4167E-C815-411A-BC29-6B16DB9586E0 Q38779535-3267F3F1-2E58-4122-842D-53ABF5314336 Q39747466-32E4F10F-F2D3-410B-99BD-8AB8EACA1522 Q50941259-6B175F7B-4759-4CB2-9247-C38A9A3E1E0A

P2860

Bactericidal activity of besifloxacin against staphylococci, Streptococcus pneumoniae and Haemophilus influenzae.

http://www.wikidata.org/entity/Q40953254

description

2010 nî lūn-bûn

@nan

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

2010年论文

@zh

2010年论文

@zh-cn

name

Bactericidal activity of besif ...... ae and Haemophilus influenzae.

@en

type

label

Bactericidal activity of besif ...... ae and Haemophilus influenzae.

@en

prefLabel

Bactericidal activity of besif ...... ae and Haemophilus influenzae.

@en

P1433

Q40953254-790FA645-0462-417B-91DF-0A8A015CB4B3

P1476

Q40953254-C571AE7C-7346-463D-A712-9B66FF03756E

P2093

Q40953254-24D04A85-E12C-4932-BD90-23F42B5FE8DB

Q40953254-653390C3-4B4C-4F5E-B99F-C31D63E16AA9

Q40953254-866F9772-90E4-4DB2-92A8-FA85B2A5445B

Q40953254-90D8452F-DE88-4655-9254-B4D168FE88CB

Q40953254-C234901B-22CA-4F4A-ADDD-ABE85B1011CE

P2860

Q40953254-0F56E14D-8FDF-466D-9760-F6C99FB39239

Q40953254-1037DCCD-23B6-4759-8204-37BD54AC51F3

Q40953254-13112D4A-168A-45C6-84E3-EDBC648DB24F

Q40953254-18AB9359-48BF-4A42-B98F-16E9913C20B6

Q40953254-2AC8DF63-FF39-44BD-8463-55DC807E4C09

Q40953254-2DE2C8C4-9BCE-444B-80A1-CFD3E050DF17

Q40953254-2E92BE2D-3065-449B-BB42-DDADACFB71AD

Q40953254-62956180-1F63-40B7-B741-2AD5734ACB1F

Q40953254-66CFBD66-B1BC-46F7-A806-F24D99C31DD2

Q40953254-67EB9902-3FFD-4334-9A02-AEDD838C2514

P304

Q40953254-10094E73-4CA6-4466-B69E-46B7CD7355B2

P31

Q40953254-5FE99F24-286E-4DE2-9E88-6287E571E299

P356

Q40953254-3CCEC530-1967-4A26-BEE2-BA7E8971A914

P407

Q40953254-5B5BEEE8-17AE-4007-8232-B6C26E9CD256

P433

Q40953254-2DDEBA6C-41EB-4B87-BA22-93A2B406C8B8

P478

Q40953254-499D7C4C-C77A-449E-A1E6-06CE093B15D8

P577

Q40953254-A68CE8E1-7731-4D93-A4A4-14139ED3F3BD

P5875

Q40953254-0E662C12-B561-47E2-AF30-80798C17DC50

P698

Q40953254-2BBCBE57-BB2D-4EA6-9942-B2DAFA8C13F6

P932

Q40953254-F018A9F7-3E38-4BD8-8FD2-1A1652FAA074

P356

P1433

Journal of Antimicrobial Chemotherapy

P1476

Bactericidal activity of besif ...... ae and Haemophilus influenzae.

@en

P2093

Chris M Pillar

http://www.w3.org/2001/XMLSchema#string

Christine K Hesje

http://www.w3.org/2001/XMLSchema#string

Christine M Sanfilippo

http://www.w3.org/2001/XMLSchema#string

Timothy W Morris

http://www.w3.org/2001/XMLSchema#string

Wolfgang Haas

http://www.w3.org/2001/XMLSchema#string

P2860

Activities and postantibiotic effects of gemifloxacin compared to those of 11 other agents against Haemophilus influenzae and Moraxella catarrhalis

Application of fluoroquinolone pharmacodynamics.

Nonclinical pharmacodynamics, pharmacokinetics, and safety of BOL-303224-A, a novel fluoroquinolone antimicrobial agent for topical ophthalmic use.

Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria

Activity of and resistance to moxifloxacin in Staphylococcus aureus.

Mutations in the quinolone resistance determining region in Staphylococcus epidermidis recovered from conjunctiva and their association with susceptibility to various fluoroquinolones

Quinolone-resistant Haemophilus influenzae in a long-term-care facility: nucleotide sequence characterization of alterations in the genes encoding DNA gyrase and DNA topoisomerase IV.

Spectrum and mode of action of azithromycin (CP-62,993), a new 15-membered-ring macrolide with improved potency against gram-negative organisms.

Besifloxacin ophthalmic suspension 0.6% in patients with bacterial conjunctivitis: A multicenter, prospective, randomized, double-masked, vehicle-controlled, 5-day efficacy and safety study.

Alteration in the GyrA subunit of DNA gyrase and the ParC subunit of DNA topoisomerase IV in quinolone-resistant clinical isolates of Staphylococcus epidermidis.

P304

1441-1447

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/JAC/DKQ127

http://www.w3.org/2001/XMLSchema#string

P407

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

65

http://www.w3.org/2001/XMLSchema#string

P577

2010-04-30T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

43534773

http://www.w3.org/2001/XMLSchema#string

P698

20435780

http://www.w3.org/2001/XMLSchema#string

P932

2882870

http://www.w3.org/2001/XMLSchema#string